Treasury Proposes Limits on U.S. Investments in Chinese Biotech

• The U.S. Treasury Department proposed restrictions on U.S. investments in Chinese biotech companies.
• The proposal aims to limit certain investments while still allowing licensing agreements.
• The biopharma industry is divided on the necessity and impact of these restrictions.
• Debate centers on whether to focus on boosting domestic R&D or preventing Chinese investments.
• The proposal is currently under review, with no final decisions made.